View clinical trials related to Kidney Insufficiency.
Filter by:Primary Objectives: - Conversion of a positive donor specific cross-match to a living donor to a negative cross-match thereby allowing successful renal transplantation. - Transplant success or failure following the desensitization protocol. - Determination of the effect of rituximab on the kinetics of donor specific antibodies (DSA). - Determination of the effect of rituximab on the kinetics of B-cell subpopulations in peripheral blood and/or secondary lymphoid organs (lymph node biopsies at time of transplant, if available) in both responders and non-responders using flow cytometry and/or immunohistochemistry. Secondary Objectives: -Decrease in incidence of humoral rejection to less than 50 % at 1 year.
The purpose of this study is to determine if administration of rituximab blocks the development of donor specific antibodies (DSA) in transplant recipients who have developed renal dysfunction and DSA after renal transplant. It is hoped that by blocking DSA production renal function will stabilize or improve.